OBJECTIVE: To assess the role of inhibin B in the evaluation of male factor infertility. DESIGN: Prospective study. SETTING: Reproductive endocrinology clinic. PATIENT(S): Seventy-five patients with infertility problems (mean age 31.2 +/- 7.5 years) and 12 controls (32.1 +/- 8.8 years) with proven fertility. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Semen analysis was performed according to World Health Organization guidelines. Testicular volume was assessed with the Prader's orchidometer. Serum levels of inhibin B (pg/mL), LH (mIU/mL), FSH (mIU/mL), prolactin (micro IU/mL), and testosterone (nmol/L) were assessed. RESULT(S): The mean +/- SEM inhibin B and testosterone levels were significantly lower in the patients than in the controls (inhibin B: 116.4 +/- 11.7 vs. 181.2 +/- 20.9, P=.008; testosterone: 13.6 +/- 0.9 vs. 25.1 +/- 2.9, P=.008). In general, sperm count and testicular volume in the patients were significantly and positively correlated with inhibin B (sperm count: r = 0.476, P<.0001; testicular volume, right: r = 0.57, P=.0001; left: r = 0.53, P=.0001); the inhibin B-FSH index was negatively correlated with FSH. Inhibin B was more strongly correlated with testicular volume and semen parameters than FSH. Inhibin B in the patients was negatively correlated with FSH (r = -0.723, P=.0001) and LH (r = -0.52, P=.0001) and was positively correlated with testosterone (r = 0.4, P=.0013). CONCLUSION(S): Inhibin B measurement is a better marker of fertility status than FSH and LH. Concentration of inhibin B in patients with infertility may provide useful information on spermatogenesis and possibly serve as a more direct marker of spermatogenesis than FSH.
OBJECTIVE: To assess the role of inhibin B in the evaluation of male factor infertility. DESIGN: Prospective study. SETTING: Reproductive endocrinology clinic. PATIENT(S): Seventy-five patients with infertility problems (mean age 31.2 +/- 7.5 years) and 12 controls (32.1 +/- 8.8 years) with proven fertility. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Semen analysis was performed according to World Health Organization guidelines. Testicular volume was assessed with the Prader's orchidometer. Serum levels of inhibin B (pg/mL), LH (mIU/mL), FSH (mIU/mL), prolactin (micro IU/mL), and testosterone (nmol/L) were assessed. RESULT(S): The mean +/- SEM inhibin B and testosterone levels were significantly lower in the patients than in the controls (inhibin B: 116.4 +/- 11.7 vs. 181.2 +/- 20.9, P=.008; testosterone: 13.6 +/- 0.9 vs. 25.1 +/- 2.9, P=.008). In general, sperm count and testicular volume in the patients were significantly and positively correlated with inhibin B (sperm count: r = 0.476, P<.0001; testicular volume, right: r = 0.57, P=.0001; left: r = 0.53, P=.0001); the inhibin B-FSH index was negatively correlated with FSH. Inhibin B was more strongly correlated with testicular volume and semen parameters than FSH. Inhibin B in the patients was negatively correlated with FSH (r = -0.723, P=.0001) and LH (r = -0.52, P=.0001) and was positively correlated with testosterone (r = 0.4, P=.0013). CONCLUSION(S): Inhibin B measurement is a better marker of fertility status than FSH and LH. Concentration of inhibin B in patients with infertility may provide useful information on spermatogenesis and possibly serve as a more direct marker of spermatogenesis than FSH.
Authors: Lisa B Kenney; Laurie E Cohen; Margarett Shnorhavorian; Monika L Metzger; Barbara Lockart; Nobuko Hijiya; Eileen Duffey-Lind; Louis Constine; Daniel Green; Lillian Meacham Journal: J Clin Oncol Date: 2012-05-29 Impact factor: 44.544
Authors: Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff Journal: Endocr Rev Date: 2014-07-22 Impact factor: 19.871
Authors: P Cavarzere; M Sulpasso; E Maines; M Vincenzi; R Gaudino; E Monti; C Chironi; L Tatò; F Antoniazzi Journal: J Endocrinol Invest Date: 2011-06-07 Impact factor: 4.256
Authors: Daniel M Green; Liang Zhu; Nan Zhang; Charles A Sklar; Raymond W Ke; William H Kutteh; James L Klosky; Sheri L Spunt; Monika L Metzger; Fariba Navid; DeoKumar Srivastava; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2013-02-19 Impact factor: 44.544